XML 104 R42.htm IDEA: XBRL DOCUMENT
v3.22.0.1

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2019 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019
Revenue related to Sanofi agreement: |  |  |  |
Total |  | $ 110,701 | $ 118,192 | $ 102,428
Novartis Institutes for BioMedical Research, Inc. |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Total |  | 37,944 | 5,252 | 0
Novartis Institutes for BioMedical Research, Inc. | Recognition of license and stand-ready fee |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Total |  | 29,945 | 4,143 | 0
Novartis Institutes for BioMedical Research, Inc. | Research services |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Total |  | 7,999 | 1,109 | 0
Biogen MA, Inc. |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Total |  | 42,300 | 27,901 | 0
Biogen MA, Inc. | Recognition of license and stand-ready fee |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Total |  | 29,224 | 21,356 | 0
Biogen MA, Inc. | Research services |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Total |  | 13,076 | 6,545 | 0
Kite Pharma, Inc. |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Total |  | 25,453 | 28,608 | 34,350
Kite Pharma, Inc. | Recognition of license and stand-ready fee |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Total |  | 24,977 | 25,046 | 24,977
Kite Pharma, Inc. | Research services |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Total |  | 476 | 3,562 | 9,373
Pfizer, Giroctocogene Fitelparvovec |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Total |  | 0 | 34,449 | 39,359
Pfizer, Giroctocogene Fitelparvovec | Recognition of license and stand-ready fee |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Total | $ 8,700 | 0 | 3,111 | 15,697
Pfizer, Giroctocogene Fitelparvovec | Milestone achievement |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Total |  | 0 | 31,338 | 23,662
Pfizer C9ORF72 |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Total |  | 0 | 12,985 | 1,827
Pfizer C9ORF72 | Recognition of license and stand-ready fee |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Total |  | 0 | 7,985 | 1,827
Pfizer C9ORF72 | Milestone achievement |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Total |  | 0 | 5,000 | 0
Sanofi S.A. |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Total |  | 3,114 | 5,322 | 22,680
Sanofi S.A. | Recognition of license and stand-ready fee |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Total |  | 34 | 298 | 3,494
Sanofi S.A. | Research services |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Total |  | 3,057 | 4,823 | 6,367
Sanofi S.A. | Milestone achievement |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Total |  | $ 23 | $ 201 | $ 12,819

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenuesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_ResearchServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerGiroctocogeneFitelparvovecMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_SanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |